Long -term outcome of Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemia

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591037
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Circulatory organs internal medicine
• Research Institution: Niigata University
• Principal Investigator: OZAWA Takuya 新潟大学, 医歯学系, 助教 (70467075)
• Co-Investigator(Kenkyū-buntansha): TOBA Ken 新潟大学, 医歯学総合病院, 講師 (60313540) ; HANAWA Haruo 新潟大学, 医歯学系, 准教授 (40282983) ; ODA Masato 新潟大学, 医歯学総合病院, 医員 (60572724) ; YANAGAWA Takao 新潟大学, 医歯学総合病院, 特任助教 (10625586) ; MORIYAMA Masato 新潟大学, 医歯学系, 助教 (30598131) ; MASUKO Masayoshi 新潟大学, 医歯学総合病院, 准教授 (70397115) ; SUDA Masayoshi 新潟大学, 医歯学総合病院, 医員 (70714509)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 臨床心血管病態学 / 血管再生 / 赤芽球 / 細胞療法 / 体外増幅

Outline of Final Research Achievements

We investigated the efficacy of a novel cell therapy by implantation of ex vivo expanded immature erythroblasts cultured from hematopoietic stem/precursor cells. 13 patients with severe chronic limb ischemia accompanied by peripheral artery disease, Burger's disease or collagen arteritis were enrolled in a pilot clinical trial of the novel cell therapy by transplantation of ex-vivo expanded immature erythroid cells (EVEETA). In the clinical trial, most clinical symptoms such as rest pain and skin ulcers improved in 4 weeks, and did not recur in the one-year follow-up. A small amount of bone marrow (mean amount, 71.2 ± 20.1 mL) was collected from the patients under local anesthesia. After 14 days of culture, the number of erythroblasts increased to enough level for in vivo angiogenesis therapy (64.5 ± 41.3 times from baseline). No adverse events were observed in any of the patients.

Free Research Field

医歯学系